Baricitinib Improvement Across Regions in Atopic Dermatitis Patients with Baseline Body Surface Area up to 40% and Severe Itch

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Effectiveness of Baricitinib in Treating Atopic Dermatitis in Difficult-to-treat Areas: A Retrospective Real-world Study2026
2. 2Safety of Baricitinib for the Treatment of Atopic Dermatitis in Adults Over a Median of 1.6 and up to 4.6 Years Treatment: Final Integrated Analysis of Eight Clinical Trials2025
3. 3Baricitinib for Itch-Dominant Atopic Dermatitis: A 52 Weeks Baricitinib Real-World Experience in Korea2026
4. 4AD-REAL: A Prospective, Multinational, Observational Cohort Study of Clinical Effectiveness and Treatment Discontinuation of Oral Systemics for Moderate-to-Severe Atopic Dermatitis2026
5. 5Real-world effectiveness and safety of baricitinib including its effect on biomarkers and laboratory data in Japanese adult patients with atopic dermatitis: a single-center retrospective study2024 · 9 citations